cyrilzakka/clinical-trials huggingface dataset:
Effect of Chest Physiotherapy on the Development of Preterm Infants.

The aim of this study is to investigate the effect of the stimulation of "reflex rolling" from the Vojta method and the effect of the expiratory flow increase technique on the development of the preterm infants. In the same way, it will be assessed whether the application of these techniques produce pain.

This application will be carried out in preterm infants of less than 32 weeks of gestation with neonatal respiratory distress syndrome (SDR) and carriers of mechanical ventilation. The intervention will take place in the neonatal intensive care unit (NICU) The intervention period is one month (4 weeks) and different follow-ups will be carried out at term age, at 3, 6, 9 and 12 months of corrected age.


Eligibility Criteria:
Inclusion Criteria:

* Preterm Infants \<32 gestational age
* Admitted to the NICU
* With SDR
* Hemodynamically stable
* Stable convulsive pictures
* Controlled thermoregulation
* Mechanical ventilation (invasive or non-invasive)
* Parents / guardians of legal age, with sufficient cognitive ability to understand consent
* Signature of consent

Exclusion Criteria:

* Periventricular leukomalacia
* Grade III and IV intraventricular hemorrhage
* Rib fracture
* Asphyxia at birth
* Necrotizing enterocolitis \> or = II B

Abandoned Criteria:

* Appearance of any of the complications mentioned above
* Hospital transfer
* Hospital discharge (if the intervention at home cannot be followed)
* Voluntary decision of parents / guardians to abandon the study
* Medical decision
A Trial of the May Health Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With PCOS Infertility

The objective of this study is to provide preliminary evidence for the safety and effectiveness of the May Health Kit in transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.


Eligibility Criteria:
Candidates for this study must meet ALL of the following criteria:

Inclusion criteria for female participants:

1. Age: ≥ 18 to ≤ 40 years
2. Diagnostic of PCOS confirmed by at least 2 of 3 Rotterdam criteria, defined as:

   2.1 Infertility associated with chronic anovulation or oligomenorrhea, defined as spontaneous intermenstrual periods of ≥35 days or a total of ≤9 menses per year 2.2 Ultrasonographic evidence of PCOS (ovarian volume ≥ 10ml and/or follicle number per ovary of ≥ 20) 2.3 Evidence of hyperandrogenaemia: either clinical (hirsutism or acne) or biochemical (raised serum concentration of androgens (testosterone ≥ 2.5nmol/l, or FAI \> 4)
3. Ovarian accessibility: determined by ability to bring transvaginal ultrasound transducer into close proximity to ovaries
4. Resistance to first-line pharmacological treatment, defined as at least 2 consecutive non-ovulatory cycles, including at least 1 cycle at the highest dose deemed clinically relevant for the patient
5. At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years
6. Willing to comply with protocol-specified follow-up evaluation
7. Signed informed consent

   Couple inclusion criteria:
8. Normal sperm parameters based on WHO 2000 criteria (concentration⩾ 15 million/mL, motility A+B ⩾ 32%, normal forms ⩾ 4%).
9. Ability to have regular intercourse during the study
10. No previous sterilization procedures (vasectomy, tubal ligation) that have been reversed

Candidates will be excluded from the study if ANY of the following conditions apply:

1. Pregnant, parturient or breastfeeding women
2. Marked obesity, BMI \> 35
3. Marked hyperandrogenism (FAI \> 15)
4. Previous ovarian surgery: LOD, endometriosis surgery, ovarian cysts surgery, patients with known or suspected periovarian adhesions.
5. Subject with pacemaker, defibrillator or other active implant
6. Subject is currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study
7. Lack of capacity to give informed consent (individuals deprived of their liberty subject to a legal protection measure or who are unable to express their consent, individuals under guardianship or curatorship)
A Single Session of tDCS (Transcranial Direct Current Stimulation) Improves Endurance for 30 Minutes

Healthy recreational athletes will undergo a session of anodal tDCS (transcranial direct current stimulation) or sham tDCS.

The primary outcome is an isokinetic evaluation of their hamstrings' and quadriceps' strength before and after each session

Healthy recreational athletes will be recruited through social media and advertisements.

Each subject came to the Liege University Hospitals' isokinetic lab. Each session began with strapping the subjet into the isokinetic machine, making sure that all the settings were adapted to the subject. Then, each subject underwent a concentric and eccentric isokinetic test of their lower limbs (dominant or non-dominant side depending on their group). Subjects then received either anodal tDCS, of sham tDCS. Neither the evaluator or the subject knew which they were receiving. Immediately following tDCS, there was a another isokinetic test, and 30 minutes after the second test, a subjects underwent a third test.

Eligibility Criteria:
Inclusion Criteria:

* Between 3 and 5 hours of sport a week
* Right handed and footed

Exclusion Criteria:

* One on the TSST (in high and relatively high risk sections)
* Previous neurological or orthopedic pathologies affecting limbs
Evaluating the Effectiveness of a Headache Management Program in Primary Care Settings

Between January 2020 to August 2021, fifty percent of patients referred from Geisinger's primary care sites to Neurology for headaches did not trial appropriate first line therapy prior to referral, and there was limited access available at Geisinger's Neurology department. This project was initiated to improve patient experience, management of headache, and provider experience as it relates to headache management. Geisinger's Neurology department, pharmacy department, and Community Medicine Service Line (CMSL) sites have collaborated to develop a Headache CarePath (i.e., a best practice alert containing: an EPIC headache assessment, Express Lane for prescriptions, and Ask-a-doc button for Neurology consult) and piloted at 2 CMSL sites (Woodbine, Selinsgrove) to gain some initial feedback. The feedback has been incorporated into best practice alert (BPA) language and criteria. The project team now plans to implement this CarePath to half of CMSL sites first while the other half of CMSL sites will continue to practice the standard of care as of today. The team will evaluate the impact of this CarePath on patient outcomes \[change in Headache Impact Test-6 (HIT-6) scores, change in the frequency of headaches, and change in pain intensity\], emergency department (ED) visits, number of referrals to Neurology for headache, and prescribing of headache medications by comparing the measures in clinics that had the CarePath implemented to those that did not. Patient outcomes will be collected by Geisinger's Survey Core, which will reach out telephonically to patients to ask about the status of their headaches (HIT-6, frequency, intensity of headaches, M-TOQ-5). Other measures will be collected and analyzed using secondary data sources such as electronic health record (EHR) data. The initial implementation is planned for 6-9 months. The findings from this evaluation will help the CarePath team identify any remaining opportunities or guide the direction of its future enhancements of the CarePath tools. The results of this evaluation will be shared with the Geisinger leadership to demonstrate its value to the organization.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients ≥ 18 years of age for whom the Headache BPA fires at the time for their PCP encounter
* New or returning patients with headache as visit diagnosis or chief complaint for the office visit or telemedicine encounter
* Have a minimum baseline HIT-6 score of ≥ 50 points OR
* Headache frequency of ≥ 12 days with headache or migraine complaint in the last 3 months

Exclusion Criteria:

* Patients at the pilot sites (i.e., woodbine, selinsgrove)
* Patients diagnosed with secondary headache disorders (eg, brain tumors) or serious systemic illness (eg, uncontrolled hypertension, hepatic or renal failure, cardiac failure) or acute infectious illness (eg, flu, sinusitis).
* Patients with headaches as a symptom due to fall/injury
* Pregnant women
Thyroid Function and Autoimmunity in Subfertility Women and Assisted Reproductive Therapy

The assessment of ovarian reserve is well established based on the dosage of anti-Mullerian hormone (AMH). The clinical applicability of detecting thyroid autoantibodies levels has been discussed as a potential marker of low-grade inflammation. There are no studies about the detection of these autoantibodies in infertile women. Our objective is to evaluate the association between ovarian reserve and thyroid function and its autoimmunity in infertile women seeking for assisted reproductive treatment (ART).Evaluation ot thyroid function in the first trimester in also be evaluated in women submitted to ART.

The assessment of ovarian reserve is well established based on the dosage of anti-Mullerian hormone (AMH). The clinical applicability of detecting thyroid autoantibodies levels has been discussed as a potential marker of low-grade inflammation. There are no studies about the detection of these autoantibodies in infertile women. Evaluation of TSH profile during ovarian stimulation in ART is also debated in literature with conflicting results. Our objective is to evaluate the association between ovarian reserve and thyroid function and its autoimmunity in infertile women seeking for assisted reproductive treatment (ART) and TSH profile during ovarian stimulation and during the first trimester.

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria were: women attended in the outpatient clinic with baseline exams before ART and during ovarian stimulation between July 2021 and July 2023

Exclusion Criteria:

* Exclusion criteria were: patients with known clinical hypothyroidism, patients using medications that may influence the hypothalamic-pituitary-thyroid axis, such as glucocorticoids in supraphysiological doses; or that could interfere with thyroid hormone metabolism (lithium, amiodarone and aspirin in anti-inflammatory dosages).
The Finnish Study of Intraoperative Irrigation Versus Drain Alone After Evacuation of Chronic Subdural Hematoma (FINISH)

FINISH-trial is a prospective, randomized, controlled, parallel group non-inferiority trial comparing single burr-hole evacuation of chronic subdural hematoma (CSDH) with intraoperative irrigation (IR) and evacuation of CSDH without irrigation (N-IR).

FINISH-trial is a prospective, randomized, controlled, parallel group non-inferiority trial comparing single burr-hole evacuation of chronic subdural hematoma (CSDH) with intraoperative irrigation (IR) and evacuation of CSDH without irrigation (N-IR). In both groups, a passive subdural drain is used for 48 hours as a standard of treatment. The study will be conducted in all five neurosurgical departments in Finland. To determine whether operation without irrigation results in non-inferior outcome to operation with irrigation, we will randomize 426 patients into two groups and follow them up for 6 months using recurrence rates as the primary outcome. Secondary outcomes in our study include mortality, neurological outcome and complications.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a symptomatic unilateral or bilateral CSDH requiring burr-hole evacuation

  o Predominantly hypodense or isodense on imaging (CT/MRI).
* Clinical symptoms correlating with the CSDH
* Patients with bilaterally operated CSDHs will be treated with the same protocol on both sides and analyzed as a single study participant

Exclusion Criteria:

* CSDH requiring surgical treatment other that burr-hole evacuation (e.g. craniotomy)
* CSDH in a patient who has a cerebrospinal fluid shunt
* Patients who have undergone any intracranial surgery before
* Comatose patients (GCS 8 or lower) with absent motor responses to painful stimuli; decerebrate or decorticate posturing
* Patient's postoperative cooperation is suspected to be insufficient for drain usage, i.e. disoriented or semiconscious patient
* Patient has a hematogenic malignancy that has obtained active treatment within the previous five years
* Patient has a central nervous system tumor or malignancy
* Patient has acute infection with fever and requires antibiotic treatment at the moment
* Patient has a high risk of life-threatening thrombosis (e.g. recent coronary stent, recent pulmonary embolism, low cardiac valve replacement) and discontinuation of antithrombotic medication is not recommended
Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen

Comparison of bowel preparation using 2 liter polyethylene glycol regimen plus elobixibat Versus 4-Liter polyethylene glycol regimen. This study based on hypothesis that show Boston bowel preparation scale which 2L PEG regimen plus Elobixibat have result no significant difference from 4L PEG regimen

The trial study in participant who visit to Rajavithi hospital for indication of colonoscopy such as Colorectal cancer screening, Iron deficiency anemia, Chronic diarrhea, chronic constipation, abdominal pain, unintentional weight loss, History of stool occult blood test , abnormal finding from imaging

Randomized participant as above in to two group as bowel preparation regimen Group 1 the participant recieved Polyethylene glycol 2 liter split dose plus Elobixibat 10 milligram.

Group 2 the participant recieved Polyethylene 4 liter split dose

Result of the study show the difference of 2 regimen of bowel preparation which regimen better than another by measuring cleanliness of bowel preparation. The cleanliness of bowel preparation measured by Boston bowel preparation scale

Eligibility Criteria:
Inclusion Criteria:

* Adute aged 18-80 year old
* Indication for colonoscopy(one selected)

  1. Colorectal cancer screening
  2. Stool occult blood test positive
  3. History of colonic polyp
  4. abdominal pain
  5. Iron deficiency anemia
  6. Chronic diarrhea
  7. chronic constipation
  8. Unintentional weight loss
  9. Gastrointestinal bleeding
  10. Abnormal imagind study
* Participant acceptconsent information

Exclusion Criteria:

* Pregnancy or lactation
* Gastroparesis, gastric outlet obstuction
* Bowel obstruction
* Gastrointestinal tract surgery
* Inflammatory bowel disease
* ASA(American society of anesthesiologist physical status) status \> or = 4
* Allergic to Elobixibat or PEG
* Chronic kidney disease stage 4-5(GFR \<30 ml/min)
* Biliary tract obstruction
* Previous history of inadequate bowel preparation
ER2 and Deep Learning for Prediction of Adverse Health Outcomes

An Emergency Department (ED) visit for an older adult is a high-risk medical intervention. Known adverse events (AE) include delirium, prolonged ED or hospital stay, hospitalization, recurrent ED visits and hospital death. These happen in a growing proportion in ED visitors over age 65 are over who are represented in ED visits.

Tools predicting AEs in the ED are of paramount importance to help decision-making on patient triage and disposition. They can help identify areas of unmet needs for seniors in order to develop targeted actions. Multiple scoring systems including "Programme de recherche sur l'intégration des services de maintien de l'autonomie" (PRISMA-7), Identification of Seniors at Risk (ISAR), Clinical Frailty Scale (CFS), Brief Geriatric Assessment (BGA) have extensively been studied in the ED and other settings for various outcomes. These tools rely on a simple scoring system that minimally trained staff can reliably and quickly administer. Doing otherwise is unlikely to be applicable to daily clinical practice.

As prediction accuracy has not significantly improved in the past decade, perhaps new analysis strategies are necessary. The current hype surrounding deep learning comes from better and cheaper hardware and the availability of simple and open-source libraries supported by large companies and a broad community of users. Hence, implementing deep learning (DL) algorithms is now open to a wide range of settings, including medical care in a standard clinical practice. DL has been shown to be more accurate than the average board-certified specialist on very specific tasks. Prediction of various clinical outcomes has produced less dramatic results, perhaps as traditional (non-DL) models already outperformed clinicians for many disease states. Published DL approaches applied to outcome prediction in the ED have focused on acutely ill adults in general, specific conditions or administrative issues such as admitting department or ED overcrowding. None have targeted a specific age group like older ED visitors.

An important caveat to many DL approaches is interpretation of results. To develop interventions based on targeted features associated with AEs in a given model, it has to be somewhat transparent. If multiple layers of NNs improve prediction compared to linear regression, they often provide no clinically relevant insight on how and which variables interact to yield that result.


Eligibility Criteria:
Inclusion Criteria:

* Age above 75 years old
* Unplanned Emergency department visit

Exclusion Criteria:

* Do not meet inclusion criteria
Aerobic Training Versus Behavioral Intervention to Increase Physical Activity in Patients With Asthma

To compare the effects of aerobic training and behavioural intervention to increase physical activity in the clinical control of asthma and in the quality of life of patients with asthma.

Adult participants of both genders with moderate to severe asthma, not physically active, will be evaluated after being informed about the study, agreeing and signing the informed consent form. Participants will be randomized to aerobic training or behavioral intervention group. Both interventions will consist of 8 weeks. Aerobic training will be performed on a treadmill (2xweek; 45 min/session). The behavioral intervention will be a program to increase physical activity (1xweek; up to 90 min / session). The maximum HR will be estimated according to the Tanaka's equation (208 - 0.7 x age).

Eligibility Criteria:
Inclusion Criteria:

1. Participants not physically active;
2. Uncontrolled asthma (ACQ\>1,5);
3. Diagnosis of asthma based on the recommendations of the Global Initiative for Asthma (GINA 2020);
4. Be under outpatient follow-up at the Pulmonology or Immunology service of the University of Sao Paulo General Hospital;
5. Be under outpatient medical treatment for at least six months, with a stable clinical condition for at least 30 days;
6. Being using optimized drug therapy for asthma.

Exclusion Criteria:

1. Participation in another research protocol;
2. Difficulty in understanding any of the questionnaires used;
3. Practitioners of regular physical activity;
4. Pregnancy and psychiatric problems that make it difficult to understand the questionnaires and the study protocol;
5. Presence of another chronic lung, neurological or musculoskeletal disease that hinders or prevents physical activity;
6. Patients who are smokers or ex-smokers (who have quit smoking for less than 1 year or who have smoked more than 15 pack-years).
Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy

The purpose of this randomized intervention study is to investigate the effects and biological mechanisms of a supervised 12-week progressive resistance training on fatigue and immunological and inflammatory biomarkers in breast cancer patients during adjuvant radiotherapy. To determine the effect of the exercise itself beyond potential psychosocial effects due to attention by trainers or the group support, patients in the control group have a comparable training schedule (i.e. 60 min, twice a week, for 12 weeks) but with relaxation training (Jacobsen method).


Eligibility Criteria:
Inclusion Criteria:

* histologically confirmed primary breast cancer, stage I-III, after lumpectomy or mastectomy, indication for adjuvant radiotherapy
* BMI: 18-40
* ability to understand and follow the study protocol

Exclusion Criteria:

* contraindication for exercise
* participation in the BEATE trial or another systematic resistance or relaxation training
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.

Hypothesis: a combined strategy of tuberculin skin test (TST) followed by QuantiFERON-TB Gold In-Tube (QFT-IT) to confirm positivity (tuberculosis infection,in contact-tracing study will allow avoiding unnecessary preventive treatment without increasing rates of tuberculosis cases among contacts screened.

Aim of the study: to compare a combined strategy of the TST and the QFT-IT with TST alone for the diagnosis of tuberculosis infection and for therapeutic decision in contact tracing study.

Design and setting: Prospective, multicentre, comparative study in 12 hospitals in Spain.

Study population: 870 subjects, household contacts of patients with culture positive pulmonary and/or laryngeal tuberculosis will be randomized to one of two strategies: Arm A (standard practice), in which treatment decisions will be based on the TST result, and Arm B (experimental), in which treatment decisions will be based on the QFT result.

Interventions: participants in arm A will undergo TST; participants in arm B will undergo TST, and, in case of a positive result, QFT-IT as well. Participants with positive TST (arm A) and positive QFT-IT (arm B) will be diagnosed with tuberculosis infection and will be treated with isoniazid for 6 months. All participants will be followed for two years.

End-points of evaluation: development of tuberculosis and proportion of subjects for whom treatment is prescribed in each arm.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years.
* Close contact of a pulmonary and/or laryngeal tuberculosis case.
* Written informed consent.

Exclusion Criteria:

* HIV infection.
* Immunosuppression other than HIV, such as decompensated liver disease, chronic renal failure, corticosteroids treatment, malignancy under chemotherapy therapy.
* Prior tuberculosis or positive TST.
* Strain resistant to Isoniazid (index case).